Neuronetics Inc (STIM) 뉴스

STIM under $3

Going to do it again!

Got 6% 2 hours

Momentum play!

STIM 10Q due March 5

STIM new 52 week low

STIM new 52 week low

$STIM - 👆Up 6.8% Pre-Market/ Current Price $2.06
Reports Record Q2 '23 Financial & Operating Results
👉Q2 '23 revenue of $17.6m, an increase of 8% over the Q2 '22
👉U.S. treatment session revenue increased 9% over the Q2 of '22
👉Shipped 54 NeuroStar systems

Slowly moving UP. VERY INTERESTED in their technology. In time, we may be looking at a very LUCRATIVE company here.

We'll see ...

Wow - after hours filled the gap in ONE day. Very interesting ...

How big of a deal do you think today's news IS?

NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Anxious Depression
July 19 2022 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, including drug-resistant depression and obsessive-compulsive disorder (OCD), announced clearance from the U.S. Food and Drug Administration (FDA) for a new indication for its transcranial magnetic stimulation (TMS) system – NeuroStar Advanced Therapy for Mental Health – to treat anxiety symptoms for adult patients who suffer from major depressive disorder (MDD), also known as anxious depression.
“Today, we celebrate a big win for NeuroStar patients and providers,” said Keith J. Sullivan, President and CEO of Neuronetics Inc. “Many people suffering from MDD also experience anxiety symptoms, and these patients with anxious depression are more likely to be severely depressed and to have more thoughts of suicide. This new indication means providers can now describe to MDD patients the benefit of NeuroStar for improving their anxiety symptoms.”

NeuroStar is the leader in patient-focused TMS therapy having treated over 134,000 patients who completed more than 4.8 million treatment sessions. The FDA accepted Neuronetics’ use of real-world data analyzed from NeuroStar’s proprietary TrakStar® platform in granting clearance for this new indication. The TrakStar database contains digital data from patients treated with NeuroStar at over 1,000 centers. Real-world data from TrakStar is particularly valuable because it provides a large sample from a diverse patient group being treated in a clinical practice setting.

“We would like to acknowledge the contributions of healthcare providers across the country who have partnered with us to help build the world’s largest database of depression outcomes,” said Cory Anderson, VP R&D and Clinical. “Not only do we have MDD outcomes, but we also receive data on anxiety outcomes from patients with anxious depression, and these real-world results in anxious depression were an important piece of the FDA clearance.”

The TrakStar results from 664 anxious depression patients demonstrated that 65.5% achieved a clinically meaningful response which exceeded the pre-established overall study success criteria of a minimum 50% response rate (p<0.0001) and indicated a large treatment effect size of 1.4.

“A clinical presentation of anxiety symptoms in patients with MDD is typically more complex to successfully treat with currently available medications,” said Melissa Fickey, MD, founder of Embracing Life Wellness Center. “NeuroStar has presented a robust data set from over 1,300 patients showing safety and efficacy in relieving both depression and anxiety symptoms in patients with anxious depression.”

DASH, TouchStar™, and standard MDD protocols offered by NeuroStar are all now indicated to treat depression with comorbid anxiety. This clearance closely follows after NeuroStar’s announcement of an obsessive compulsive disorder (OCD) indication, which received FDA clearance in May of this year. For more information about NeuroStar Advanced Therapy for Mental Health, please visit neurostar.com

About Anxious Depression
Major depressive disorder (MDD) is a common and serious psychiatric diagnosis among adults with an estimated prevalence of 13.9M patients under treatment in the United States. Anxiety symptoms are a common co-morbidity in patients with MDD, commonly called anxious depression, with an estimated prevalence of more than 50% of MDD patients. The NeuroStar Advanced Therapy System is now indicated for treating anxiety symptoms for those who may exhibit comorbid anxiety and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.

About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decre

Guess we got a dog pile here..

UGLY day

Thank you I'll take a look. Yes it works. If they announce trials on Alzheimer's, who knows where this goes. As it is this is a solid growth company. I was surprised at the secondary offering in light of their revenues.
As for BWAY, the only negative off the cuff is that it is an Israeli company. Tend to be big sink holes...

Brains at (BWAY) is the only other company I know.

My son is an rTMS tech and tells me flat out that it works.

EB

This is a major winning technology an stock, and the board is dead??????

Looking at a solid and easy 100 dollar stock here. The treatments work!!!!

Are their any other public companies in this sector?
Thanks in advance

$STIM | #Neuronetics Inc +60% Potential Upside


Neuronetics , Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS , a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.
Average Analysts Recommendation: BUY
Average Target Price: $5.75

$4.64

$3.96

$3.85

$3.44 lovely

* * $STIM Video Chart 07-15-2020 * *

Link to Video - click here to watch the technical chart video

creeping back up HOD for next leg up :)

$3+ surge lovely

$2.88 nice

* * $STIM Video Chart 06-23-2020 * *

Link to Video - click here to watch the technical chart video

STIM Up 18.8% , UP 2,87 In AH so far. Slowly rising. Healthcare stocks HOT today...


$STIM should have a strong Open and pre market Wednesday ...especially if price keeps rising in AH,
Closed 2.09
Current 2.16

$STIM ADDING BELOW $2.15 FOR ROUND #2 ^

$STIM BELOW $2.20 DIP & RIP END OF DAY ^

Neuronetics, Inc. is commercial-stage medical technology company. The Company is focused on the design and development of medical devices to treat psychiatric disorders. The Company’s principal product is NeuroStar Advanced Therapy System. It is a non-invasive treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed magnetic field to induce electrical pulses for stimulating certain areas of the brain associated with mood. The system is used to treat adult patients with major depressive disorders. The Company offers its therapy systems to psychiatrist offices in the United States.